Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide

Drug Metabolism and Disposition

Volumn 38, Issue 10, 2010, Pages 1857-1864

  Sawamura, Ryoko ^a   Okudaira, Noriko ^a   Watanabe, Kengo ^a   Murai, Takahiro ^a   Kobayashi, Yoshimasa ^a   Tachibana, Masaya ^a   Ohnuki, Takashi ^a   Masuda, Kayoko ^a   Honma, Hidehito ^a   Kurihara, Atsushi ^a   Okazaki, Osamu ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL GLUCURONIDE; BENOXAPROFEN; CARBOXYLIC ACID; DICLOFENAC; FENCLOFENAC; FLUFENAMIC ACID; FUROSEMIDE; GEMFIBROZIL; GLUCURONIDE; HUMAN SERUM ALBUMIN; IBUFENAC; IBUPROFEN; INDOMETACIN; LEVOFLOXACIN; MECLOFENAMIC ACID; MEFENAMIC ACID; MONTELUKAST; NAPROXEN; POTASSIUM DIHYDROGEN PHOSPHATE; PROBENECID; REPAGLINIDE; TELMISARTAN; TOLMETIN; UNCLASSIFIED DRUG; ZOMEPIRAC;

ANAPHYLAXIS; ARTICLE; CORRELATION ANALYSIS; DRUG CLASSIFICATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG WITHDRAWAL; HUMAN; IN VITRO STUDY; LIVER INJURY; LIVER TOXICITY; NEUTROPENIA; PLASMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK; RISK ASSESSMENT; SERUM; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA;

ACYLATION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUFFERS; CARBOXYLIC ACIDS; DRUG TOXICITY; GLUCURONIDES; HALF-LIFE; HUMANS; LOGISTIC MODELS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; SERUM ALBUMIN;

EID: 77957114353     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034173     Document Type: Article

References (27)

1. Baba A and Yoshioka T (2009) Structure-activity relationships for degradation reaction of 1-β-O-acyl glucuronides: kinetic description and prediction of intrinsic electrophilic reactivity under physiological conditions. Chem Res Toxicol 22:158-172.
2. Bailey MJ and Dickinson RG (1999) Limitations of hepatocytes and liver homogenates in modelling in vivo formation of acyl glucuronide-derived drug-protein adducts. J Pharmacol Toxicol Methods 41:27-32.
3. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117-137.
4. Baillie TA (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889-893.
5. Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, and Lin ET (1993) Predictability of the covalent binding of acidic drugs in man. Life Sci 53:PL141-PL146.
6. Boelsterli UA (2002) Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab 3:439-450.
7. Bolze S, Bromet N, Gay-Feutry C, Massiere F, Boulieu R, and Hulot T (2002) Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab Dispos 30:404-413. (Pubitemid 34263825)
8. Castillo M and Smith PC (1995) Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab Dispos 23:566-572.
9. Dickinson RG and King AR (1991) Studies on the reactivity of acyl glucuronides-II. Interaction of diflunisal acyl glucuronide and its isomers with human serum albumin in vitro. Biochem Pharmacol 42:2301-2306.
10. Georges H, Presle N, Buronfosse T, Fournel-Gigleux S, Netter P, Magdalou J, and Lapicque F (2000) In vitro stereoselective degradation of carprofen glucuronide by human serum albumin. Characterization of sites and reactive amino acids. Chirality 12:53-62. (Pubitemid 30068905)
11. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, and Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220.
12. McGurk KA, Remmel RP, Hosagrahara VP, Tosh D, and Burchell B (1996) Reactivity of mefenamic acid 1-O-acyl glucuronide with proteins in vitro and ex vivo. Drug Metab Dispos 24:842-849. (Pubitemid 26274740)
13. Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, and Okazaki O (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37:1970-1977.
14. Qiu Y, Burlingame AL, and Benet LZ (1998) Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies by tandem mass spectrometry. Drug Metab Dispos 26:246-256. (Pubitemid 28182401)
15. Sallustio BC, Fairchild BA, and Pannall PR (1997) Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-β-D- glucuronide. Drug Metab Dispos 25:55-60. (Pubitemid 27045134)
16. Seitz S, Kretz-Rommel A, Oude Elferink RP, and Boelsterli UA (1998) Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 11:513-519. (Pubitemid 28242496)
17. Skonberg C, Olsen J, Madsen KG, Hansen SH, and Grillo MP (2008) Metabolic activation of carboxylic acids. Expert Opin Drug Metab Toxicol 4:425-438.
18. Smith PC, Benet LZ, and McDonagh AF (1990) Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. Drug Metab Dispos 18:639-644.
19. Smith PC, McDonagh AF, and Benet LZ (1986) Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J Clin Invest 77:934-939.
20. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-47.
21. Tesfa D, Keisu M, and Palmblad J (2009) Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 84:428-434.
22. Uetrecht J (2001) Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel 4:55-59.
23. Uetrecht J (2009) Immune-mediated adverse drug reactions. Chem Res Toxicol 22:24-34.
24. Uetrecht JP (1999) New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 12:387-395.
25. Usui T, Mise M, Hashizume T, Yabuki M, and Komuro S (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37:2383-2392.
26. Wang J, Davis M, Li F, Azam F, Scatina J, and Talaat R (2004) A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements. Chem Res Toxicol 17:1206-1216. (Pubitemid 39265876)
27. Zhou SF, Xue CC, Yu XQ, Li C, and Wang G (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687-710. (Pubitemid 350190847)